in committeehouseSession: 2025R160% healthcare relevance
HB 2103
Directs the State Board of Pharmacy to adopt rules to classify xylazine as a Schedule IV controlled substance.
Official Summary
Digest: The Act tells the State Board of Pharmacy to classify xylazine as a Schedule IV controlled substance. (Flesch Readability Score: 60.1). Directs the State Board of Pharmacy to adopt rules to classify xylazine as a Schedule IV controlled substance.
Committee
HBHHC
Sponsors
Rep Osborne
Last Action
In committee upon adjournment.
Invalid Date
Legislative Timeline
bill actionJun 27, 2025
House: In committee upon adjournment.
bill actionJan 17, 2025
House: Referred to Behavioral Health and Health Care.
bill actionJan 13, 2025
House: First reading. Referred to Speaker's desk.
Story Thread
3 events tracked · Jan 13 – Jun 27, 2025